)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Infant Bacterial Therapeutics
Infant Bacterial Therapeutics (IBT) investor relations material
Infant Bacterial Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
Continued focus on bringing IBP-9414, a live biotherapeutic for premature infants, to market, with regulatory and manufacturing milestones progressing in both the EU and US.
IBP-9414 demonstrated a 27% reduction in all-cause mortality in preterm infants in Phase III, with significant regulatory designations received.
No revenue generated; operations remain pre-commercial, with ongoing R&D and regulatory expenses.
Financial highlights
Net sales were SEK 0 for both Q2 and H1 2026, unchanged from prior periods.
Operating loss for Q2 2026 was SEK -30.1 million (vs. -20.1 million Q2 2025); H1 2026 operating loss was SEK -53.6 million (vs. -37.6 million H1 2025).
Result after tax for H1 2026 was SEK -52.7 million (vs. -35.9 million H1 2025).
Cash flow for H1 2026 was SEK -35.6 million (vs. -43.9 million H1 2025); cash balance at June 30, 2026 was SEK 108.6 million.
Equity per share at June 30, 2026 was SEK 3.94 (vs. 9.97 June 30, 2025); equity ratio was 44% (vs. 70%).
Outlook and guidance
Goal remains to submit the Biologics License Application (BLA) for IBP-9414 in the US by year-end 2026.
Capital is considered sufficient until market approval is obtained.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Infant Bacterial Therapeutics
- Operating loss widened in Q1 2026 as IBP-9414 nears FDA submission and commercialization.IBT
Q1 2026 - Losses narrowed and IBP-9414 advanced toward FDA approval, with strong cash reserves maintained.IBTQ4 2025
- IBP-9414 achieved 27% lower mortality in preterm infants; regulatory filings planned for 2026.IBTQ3 2025
- FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify.IBTQ2 2025
- Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory push.IBTQ3 2024
- 27% reduction in all-cause mortality in preterm infants, despite missed primary endpoints.IBTStudy Update
- Phase 3 trial for IBP-9414 completed; results expected Q3 2024 amid higher H1 losses.IBTQ2 2024
- FDA Breakthrough Therapy Designation for IBP-9414 accelerates IBT's market path.IBTQ1 2025
- IBP-9414 advanced to regulatory submission with increased losses but strong cash reserves.IBTQ4 2024
Next Infant Bacterial Therapeutics earnings date
Q3 202613 Nov, 2026
Infant Bacterial Therapeutics
Next Infant Bacterial Therapeutics earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage